University of Groningen
Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy?
Putri, Kurnia Sari Setio
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Putri, K. S. S. (2019). Osteoprotegerin in organ fibrosis: biomarker, actor, and target of therapy?. University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Propositions – Stellingen – Dalil OSTEOPROTEGERIN IN ORGAN FIBROSIS: BIOMARKER, ACTOR AND TARGET OF THERAPY?
Kurnia Sari Setio Putri
1. Osteoprotegerin (OPG) is secreted by (myo)fibroblasts and its production is stimulated by transforming growth factor β1 (TGFβ1) (this thesis). 2. OPG production is induced by interleukin-13 and depends on TGFβ
through a pathway involving both IL13Rα1/STAT6 and IL13Rα2/AP1 (this thesis).
3. Pro- and antifibrotic stimuli have a rapid and sensitive effect on OPG production, hence, OPG is a promising biomarker of fibrosis in various organs (this thesis).
4. More than merely a fibrosis marker, OPG may induce fibrosis by upregulating TGFβ1 expression, and might play a role in fibrogenesis. 5. Despite its bone-related name, OPG plays a broader role than just
regulating bone density. OPG also has a role in fibrotic processes in various organs (this thesis).
6. Manipulating the balance between OPG, receptor activator of nuclear factor-κB (RANK), and its ligand RANKL to reverse fibrosis may affect other organs too (e.g. bone), thus it could be important to design targeted antifibrotic therapy to avoid adverse effects (this thesis).
7. The characteristics of macrophages are influenced by stimuli and microenvironment (this thesis). So are humans.
8. In research, there is no failure. It is a success when proving something acts in practice differently than in theory (trio supervisors).
9. Don’t take your organs to heaven, heaven knows we need them here. (Somewhere on the incubator cabinet in the slicing lab).
10. One answer may lead to a hundred new questions. Researchers should never run out of questions.
